Delving into the Latest Updates on Cinobufacin with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Cinobufotalin

Target-

Mechanism-

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B, ChronicNeoplasms

Inactive Indication

Cardiovascular DiseasesHepatocellular CarcinomaLiver Cirrhosis

Originator Organization-

Active Organization-

Inactive Organization

Changhai Hospital of Shanghai

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

A prospective, randomized, positive parallel controlled, double-blind, double-dummy, multicenter, phase III clinical trial of Icartin soft capsule versus Huachansu tablet in the first-line treatment of unresectable hepatocellular carcinoma with complicated disease condition, poor prognosis, and positive composite biomarkers at baseline

Start Date01 Aug 2022

Sponsor / Collaborator

Tianjin Cancer Institute

ChiCTR-IPR-17013675 / RecruitingPhase 4IIT

Clinical study of huachansu combined with TD regimen in the newly diagnosed multiple myeloma

Start Date01 Dec 2016

Sponsor / Collaborator-

NCT02647125 / Unknown statusPhase 2IIT

A Phase II Study of Comparing Huachansu Combination With Thoracic Radiotherapy Versus Radiotherapy Alone For Esophageal Squamous Cell Carcinoma

This primary objective of the trial is to study whether the local control of Huachansu plus thoracic radiotherapy is better compared to thoracic radiotherapy alone for patients with esophageal squamous cell carcinoma. It's a phase II study, 134 patients are expected to be recruited into the trial.

Start Date01 Oct 2015

Sponsor / Collaborator

Fudan University

100 Clinical Results associated with Cinobufacin

Login to view more data

100 Translational Medicine associated with Cinobufacin

Login to view more data

100 Patents (Medical) associated with Cinobufacin

Login to view more data

89

Literatures (Medical) associated with Cinobufacin

01 Jun 2024·Animal Models and Experimental Medicine

Cinobufotalin prevents bone loss induced by ovariectomy in mice through the BMPs/SMAD and Wnt/β‐catenin signaling pathways

Article

Author: Lu, Da-Zhuang ; Hu, Meng-Long ; Zhou, Yong-Sheng ; Gu, Ran-Li ; Yu, Peng ; Zhang, Ping ; Liu, Hao ; Zhang, Xiao ; Xie, Zheng-Wei ; Zeng, Li-Jun ; Li, Yang

AbstractBackgroundOsteoporosis is a chronic bone disease characterized by bone loss and decreased bone strength. However, current anti‐resorptive drugs carry a risk of various complications. The deep learning‐based efficacy prediction system (DLEPS) is a forecasting tool that can effectively compete in drug screening and prediction based on gene expression changes. This study aimed to explore the protective effect and potential mechanisms of cinobufotalin (CB), a traditional Chinese medicine (TCM), on bone loss.MethodsDLEPS was employed for screening anti‐osteoporotic agents according to gene profile changes in primary osteoporosis. Micro‐CT, histological and morphological analysis were applied for the bone protective detection of CB, and the osteogenic differentiation/function in human bone marrow mesenchymal stem cells (hBMMSCs) were also investigated. The underlying mechanism was verified using qRT‐PCR, Western blot (WB), immunofluorescence (IF), etc.ResultsA safe concentration (0.25 mg/kg in vivo, 0.05 μM in vitro) of CB could effectively preserve bone mass in estrogen deficiency‐induced bone loss and promote osteogenic differentiation/function of hBMMSCs. Both BMPs/SMAD and Wnt/β‐catenin signaling pathways participated in CB‐induced osteogenic differentiation, further regulating the expression of osteogenesis‐associated factors, and ultimately promoting osteogenesis.ConclusionOur study demonstrated that CB could significantly reverse estrogen deficiency‐induced bone loss, further promoting osteogenic differentiation/function of hBMMSCs, with BMPs/SMAD and Wnt/β‐catenin signaling pathways involved.

31 Mar 2024·Aging

Cinobufotalin regulates the USP36/c-Myc axis to suppress malignant phenotypes of colon cancer cells in vitro and in vivo

Article

Author: Luo, Ming ; Hu, Yongjun

Ubiquitin-specific protease 36 (USP36) has been reported to exhibit oncogenic effects in various malignancies, but the function of USP36 in colon cancer progression remains indefinite. Herein, we aimed to determine the role and mechanism of USP36 in malignant phenotypes of colon cancer cells and explore the potential drug targeting USP36. Bioinformatics analyses indicated that USP36 is highly expressed and significantly related to tumor stages in colon cancer. Besides, USP36 was further up-regulated in oxaliplatin (Oxa)-resistant colon cancer cells. Colony formation, Edu staining, Transwell, wound healing, sphere formation, and CCK-8 assays were conducted and showed that the proliferation, Oxa-resistance, migration, stemness, and invasion of HCT116 cells were promoted after overexpressing USP36, while suppressed by USP36 knockdown. Mechanically, USP36 enhances c-Myc protein stabilization in HCT116 cells via deubiquitination. AutoDock tool and ubiquitin-AMC hydrolysis assay identified cinobufotalin (CBF), an anti-tumor drug, maybe a USP36 inhibitor by inhibiting its deubiquitination activity. CBF significantly prohibited proliferation, migration, invasion, and stemness of HCT116 cells and reversed Oxa-resistance, whereas enforced expression of USP36 blocked these effects. Moreover, in vivo analyses confirmed the oncogenic role of USP36 and the therapeutic potential of CBF in the malignancy of colon cancer. In conclusion, CBF may be a promising therapeutic agent for colon cancer due to its regulation of the USP36/c-Myc axis.

01 Jan 2024·Archivos Españoles de Urología

Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study

Article

Author: Dong, Yanbing ; Zhang, Feng ; Chen, Fangyuan ; Niu, Meng ; Liu, Ziyang ; Wang, Chenci

OBJECTIVETo retrospectively analyse the effects of cinobufotalin capsule combined with zoledronic acid on pain symptoms and clinical efficacy of prostate cancer patients with bone metastases.METHODSPatients with prostate cancer with bone metastasis admitted to our hospital from January 2021 to December 2022 were selected as study subjects. They were divided into the control group (treated with zoledronic acid) and the combined group (cinobufotalin capsules were added on the control group basis) according to different recorded treatment methods. The efficacies of the two groups after matching, lumbar L_1-4 bone mineral density (BMD), serum calcium, serum phosphorus, visual analogue scale (VAS) score and Karnofsky performance status (KPS) score before and after treatment were compared, and adverse reactions were statistically analysed.RESULTSA total of 102 patients were included in the study, encompassing 52 patients in the combined group and 50 patients in the control group. After 1:1 preference score matching, 64 patients were included in the two groups. No significant difference in baseline data was found between the two groups (p > 0.05). The total effective rate of the combination group was higher than that of the control group (p < 0.05). No significant differences in L_1-4 bone mineral density, serum calcium and phosphorus, VAS score and KPS score were observed between the two groups prior to treatment (p > 0.05). After treatment, the L_1-4 bone mineral density (BMD) and KPS score of the combined group decreased to less than those of the control group, the VAS score was lower than that of the control group, and the serum calcium and phosphorus level increased but less than that of the control group (p < 0.05). No significant difference in adverse reactions was found between the two groups (p > 0.05).CONCLUSIONSCinobufotalin capsule combined with zoledronic acid had ideal efficacy in the treatment of prostate cancer in patients with bone metastasis. This approach could improve their bone density and quality of life, improve their calcium and phosphorus metabolism, reduce their pain symptoms and provide increased safety. It may have an important guiding role in formulating future clinical treatment plans for patients with prostate cancer and bone metastasis.

100 Deals associated with Cinobufacin

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B, Chronic	CN	-	-
Neoplasms	CN	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	CN	Changhai Hospital of Shanghai	30 Nov 2010
Hepatitis	Phase 3	CN	Changhai Hospital of Shanghai	30 Nov 2010
Liver Cirrhosis	Phase 3	CN	Changhai Hospital of Shanghai	30 Nov 2010
Hepatocellular Carcinoma	Phase 3	CN	Changhai Hospital of Shanghai	01 Nov 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CSCO2021	Not Applicable	-	52	华蟾素注射液	hejeuqghkw(hpdrqtjnfi) = qnvblacnek wxuxwyxixl (jpdreywjuv ) View more	Positive	25 Sep 2021
				盐酸氯丙嗪	hejeuqghkw(hpdrqtjnfi) = laatswnosk wxuxwyxixl (jpdreywjuv ) View more